Compare Revvity Inc (RVTY) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Revvity Inc trades at $154.1 (market cap $16.98B), while iShares 20 Plus Year Treasury Bond ETF trades at $77.98 (market cap $47.61B). The key difference: iShares 20 Plus Year Treasury Bond ETF is far larger — about 2.8× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while iShares 20 Plus Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| RVTY | TLT | |
|---|---|---|
Market Cap | $16.98B | $47.61B |
Volume | 1,456,900 | 49,263,490 |
Sector | Health | Fixed Income |
52-Week High | $157.36 | $92.06 |
52-Week Low | $82.26 | $77.11 |
Typical Hold Time | 12 Days | 83 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.98, down 46% over five years amid a historic bond market selloff. The technical outlook is bearish with moving averages signaling continued pressure, while oscillators show neutral conditions. Recent news highlights Treasury yields reaching multi-decade highs above 5.3%, creating headwinds for long-duration bond funds despite recent dividend distributions.
The ETF faces significant interest rate risk as the Federal Reserve maintains higher rates, though current yields offer attractive income potential. Key risks include further rate hikes and inflation persistence, while potential catalysts include economic slowdowns that could drive bond prices higher. Institutional flows show mixed sentiment with recent large inflows despite price declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
